64 citations · 102 across the 8 of their papers we have counts for
8 papers
On the use of non-concurrent controls in platform trials: A scoping review
Marta Bofill Roig, Cora Burgwinkel, Ursula Garczarek +4
Platform trials gained popularity during the last few years as they increase flexibility compared to multi-arm trials by allowing new experimental arms entering when the trial alre…
Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment
Marta Bofill Roig, Guadalupe Gómez Melis, Martin Posch +1
For randomized clinical trials where a single, primary, binary endpoint would require unfeasibly large sample sizes, composite endpoints are widely chosen as the primary endpoint.…
Online control of the False Discovery Rate in group-sequential platform trials
Sonja Zehetmayer, Martin Posch, Franz Koenig
When testing multiple hypotheses, a suitable error rate should be controlled even in exploratory trials. Conventional methods to control the False Discovery Rate (FDR) assume that…
On model-based time trend adjustments in platform trials with non-concurrent controls
Marta Bofill Roig, Pavla Krotka, Carl-Fredrik Burman +9
Platform trials can evaluate the efficacy of several treatments compared to a control. The number of treatments is not fixed, as arms may be added or removed as the trial progresse…
Model-based simultaneous inference for multiple subgroups and multiple endpoints
Charlotte Vogel, Frank Schaarschmidt, Christian Ritz +2
Various methodological options exist on evaluating differences in both subgroups and the overall population. Most desirable is the simultaneous study of multiple endpoints in sever…
Endpoints for randomized controlled clinical trials for COVID-19 treatments
Lori E Dodd, Dean Follmann, Jing Wang +12
Introduction: Endpoint choice for randomized controlled trials of treatments for COVID-19 is complex. A new disease brings many uncertainties, but trials must start rapidly. COVID-…
Efficient adaptive designs for clinical trials of interventions for COVID-19
Nigel Stallard, Lisa Hampson, Norbert Benda +14
The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clin…
Adaptive Survival Trials
Dominic Magirr, Thomas Jaki, Franz Koenig +1
Mid-study design modifications are becoming increasingly accepted in confirmatory clinical trials, so long as appropriate methods are applied such that error rates are controlled.…